Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways

被引：892
|
作者：
Fearon, Kenneth C. H. [1 ]
Glass, David J. [2 ]
Guttridge, Denis C. [3 ]
机构：
[1] Univ Edinburgh, Royal Infirm, Sch Clin Sci & Community Hlth, Edinburgh EH16 4SA, Midlothian, Scotland
[2] Novartis Inst Biomed Res, Cambridge, MA 02139 USA
[3] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA
来源：
CELL METABOLISM | 2012年 / 16卷 / 02期
关键词：
SKELETAL-MUSCLE ATROPHY; TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; UBIQUITIN LIGASE ATROGIN1/MAFBX; ADIPOSE TRIGLYCERIDE LIPASE; PROTEOLYSIS INDUCING FACTOR; FOXO TRANSCRIPTION FACTORS; SYNTHASE KINASE 3-BETA; MESSENGER-RNA LEVELS; KAPPA-B ACTIVATION;
D O I：
10.1016/j.cmet.2012.06.011
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Cancer cachexia is characterized by a significant reduction in body weight resulting predominantly from loss of adipose tissue and skeletal muscle. Cachexia causes reduced cancer treatment tolerance and reduced quality and length of life, and remains an unmet medical need. Therapeutic progress has been impeded, in part, by the marked heterogeneity of mediators, signaling, and metabolic pathways both within and between model systems and the clinical syndrome. Recent progress in understanding conserved, molecular mechanisms of skeletal muscle atrophy/hypertrophy has provided a downstream platform for circumventing the variations and redundancy in upstream mediators and may ultimately translate into new targeted therapies.
引用
收藏
页码：153 / 166
页数：14
相关论文
共 50 条
  • [21] Abherrent leptin signaling in cancer cachexia
    Temple, KA
    Cheng, A
    Han, Y
    Graves, RA
    Byerley, LO
    FASEB JOURNAL, 2000, 14 (04): : A475 - A475
  • [22] CANCER CACHEXIA, METABOLIC STATES AND IATROGENIC KETOSIS
    CONYERS, RAJ
    ROFE, AM
    POTEZNY, N
    CARMAN, JA
    PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, 1981, 14 : Q4 - Q4
  • [23] Gut microbiota and metabolic aspects of cancer cachexia
    Ziemons, Janine
    Smidt, Marjolein L.
    Damink, Steven Olde
    Rensen, Sander S.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 35 (03)
  • [24] Proteomic and metabolic signaling pathways in different prognosis of gastric cancer.
    Lian, Guodong
    Wang, Daguang
    Shu, Chang
    Wei, Chengguo
    Ye, Fei
    Zhang, David Y.
    Suo, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Cancer cachexia: Metabolic alterations and clinical manifestations
    Tisdale, MJ
    NUTRITION, 1997, 13 (01) : 1 - 7
  • [26] Metabolic Biomarkers for the Early Detection of Cancer Cachexia
    O'Connell, Thomas M.
    Golzarri-Arroyo, Lilian
    Pin, Fabrizio
    Barreto, Rafael
    Dickinson, Stephanie L.
    Couch, Marion E.
    Bonetto, Andrea
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [27] A hallmark of hepatic metabolic alterations in cancer cachexia
    Kojima, Yasushi
    Mishiro, Emi
    Taketo, Makoto M.
    Soga, Tomoyoshi
    Aoki, Masahiro
    CANCER SCIENCE, 2024, 115 : 229 - 229
  • [28] "Metabolic fingerprints" of cachexia in lung cancer patients
    Frille, Armin
    Arends, Jann
    Abenavoli, Elisabetta M.
    Duke, Shaul A.
    Ferrara, Daria
    Gruenert, Stefan
    Hacker, Marcus
    Hesse, Swen
    Hofmann, Lukas
    Holm, Sune H.
    Lund, Thomas B.
    Rullmann, Michael
    Sandoe, Peter
    Sciagra, Roberto
    Sundar, Lalith Kumar Shiyam
    Toenjes, Anke
    Wirtz, Hubert
    Yu, Josef
    Sabri, Osama
    Beyer, Thomas
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (07) : 2067 - 2069
  • [29] Metabolic Changes During Cancer Cachexia Pathogenesis
    Shyh-Chang, Ng
    TRANSLATIONAL RESEARCH IN BREAST CANCER: BIOMARKER DIAGNOSIS, TARGETED THERAPIES AND APPROACHES TO PRECISION MEDICINE, 2017, 1026 : 233 - 249
  • [30] Caveolae as potential mediators of MCH-signaling pathways
    Cook, Laurie B.
    Delorme-Axford, Elizabeth B.
    Robinson, Kelsi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 375 (04) : 592 - 595
12345